ArticleTranslational cancer research2026
Tumor habitat characteristics derived from intravoxel incoherent motion for early response assessment in soft tissue sarcoma undergoing neoadjuvant radiotherapy and targeted therapy: a phase II study.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Soft tissue sarcomas (STSs) are heterogeneous malignancies with limited reliable criteria for early response assessment. Commonly used criteria, such as Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, often underperform because treatment-related changes may not translate into tumor shrinkage. This study aimed to assess the potential of intravoxel incoherent motion (IVIM)-derived tumor habitat characteristics as biomarkers for assessing the treatment responses of STS patients who received neoadjuvant radiotherapy (neo-RT) along with targeted therapy. Methods: Patients with STS of the limbs or trunk from a prospective phase II trial were selected. All patients received magnetic resonance imaging (MRI) examinations pre- and post-neo-RT and targeted therapy. K-means clustering was employed to classify lesions into subregional habitats based on IVIM parameters. Postoperative pathology classified patients into good- and poor-response groups, defined as <50% and ≥50% residual tumor cells, respectively. IVIM parameters, including mean true-diffusion coefficient ( Results: Twenty-one participants (11 males, 10 females; mean age 52.1±17.4 years) were enrolled, including 13 individuals in the good-response group and 8 in the poor-response group. K-means clustering identified three clusters based on pre- and post-treatment IVIM features. Five features that significantly differed between the good-response and poor-response groups were incorporated into individual parameter models and combined model. The area under the ROC curve of the combined model was 0.904, greatly outperforming that of RECIST 1.1 [area under curve (AUC) 0.567] and individual parameter models. Conclusions: Tumor subregional IVIM parameters can well assess the pathological response degree in STS patients undergoing neo-RT and targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.